Literature DB >> 17128681

Multiple lipid scoring system for prediction of coronary heart disease risk: application to African Americans.

Charles J Everett1, Arch G Mainous, Richelle J Koopman, Vanessa A Diaz.   

Abstract

BACKGROUND: Clinicians often obtain a panel of lipids but then only use low-density-lipoprotein (LDL) cholesterol to make clinical decisions. We previously described the multiple lipid measure, a strategy that integrates information about seven lipid measures. Our current inquiry uses the multiple lipid measure to create a scoring system and validates that system in a second cohort. METHODS AND
RESULTS: A scoring system that uses total cholesterol, high-density lipoprotein (HDL) cholesterol, LDL cholesterol and triglycerides was developed and tested. African-American participants of the Atherosclerosis Risk in Communities (ARIC) Study were used to validate the multiple lipid measure score. For nonsmokers, scores > or = 2 had a hazard ratio of 4.25 (95% CI 1.92-9.40) compared to reference scores of < or = -3 in adjusted survival analysis predicting incident coronary heart disease risk in the ARIC. The best conventional single lipid measure for nonsmokers was LDL cholesterol. Compared to LDL cholesterol <100 mg/dl, those with LDL cholesterol > or = 160 mg/dl had a hazard ratio of 2.31 (95% CI 1.13-4.75). For current smokers, the best conventional lipid measure was the total cholesterol/HDL cholesterol ratio, which was similar in predictive ability to the multiple lipid measure score. However, the multiple lipid measure score predicted an additional 10% of the cohort at risk compared to the total cholesterol/HDL cholesterol ratio.
CONCLUSIONS: The use of the multiple lipid scoring system improves the assessment of incident coronary heart disease risk and may have utility for clinicians in integrating lipid values.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17128681      PMCID: PMC2569773     

Source DB:  PubMed          Journal:  J Natl Med Assoc        ISSN: 0027-9684            Impact factor:   1.798


  22 in total

1.  Dextran sulfate-Mg2+ precipitation procedure for quantitation of high-density-lipoprotein cholesterol.

Authors:  G R Warnick; J Benderson; J J Albers
Journal:  Clin Chem       Date:  1982-06       Impact factor: 8.327

2.  Thrombogenic factors and recurrent coronary events.

Authors:  A J Moss; R E Goldstein; V J Marder; C E Sparks; D Oakes; H Greenberg; H J Weiss; W Zareba; M W Brown; C S Liang; E Lichstein; W C Little; J A Gillespie; L Van Voorhees; R J Krone; M M Bodenheimer; J Hochman; E M Dwyer; R Arora; F I Marcus; L F Watelet; R B Case
Journal:  Circulation       Date:  1999-05-18       Impact factor: 29.690

3.  Effect of blood collection and processing on radioimmunoassay results for apolipoprotein B in plasma.

Authors:  S A Brown; D F Epps; J K Dunn; A R Sharrett; J R Patsch; A M Gotto; W Patsch
Journal:  Clin Chem       Date:  1990-09       Impact factor: 8.327

4.  Apolipoprotein A-I and B levels and the risk of ischemic heart disease during a five-year follow-up of men in the Québec cardiovascular study.

Authors:  B Lamarche; S Moorjani; P J Lupien; B Cantin; P M Bernard; G R Dagenais; J P Després
Journal:  Circulation       Date:  1996-08-01       Impact factor: 29.690

5.  Reagent for the enzymatic determination of serum total triglycerides with improved lipolytic efficiency.

Authors:  U Nägele; E O Hägele; G Sauer; E Wiedemann; P Lehmann; A W Wahlefeld; W Gruber
Journal:  J Clin Chem Clin Biochem       Date:  1984-02

6.  Plasma lipid, lipoprotein cholesterol, and apoprotein distributions in selected US communities. The Atherosclerosis Risk in Communities (ARIC) Study.

Authors:  S A Brown; R Hutchinson; J Morrisett; E Boerwinkle; C E Davis; A M Gotto; W Patsch
Journal:  Arterioscler Thromb       Date:  1993-08

7.  Reference intervals for plasma apolipoprotein A-1 determined with a standardized commercial immunoturbidimetric assay: results from the Framingham Offspring Study.

Authors:  J Contois; J R McNamara; C Lammi-Keefe; P W Wilson; T Massov; E J Schaefer
Journal:  Clin Chem       Date:  1996-04       Impact factor: 8.327

8.  Reference intervals for plasma apolipoprotein B determined with a standardized commercial immunoturbidimetric assay: results from the Framingham Offspring Study.

Authors:  J H Contois; J R McNamara; C J Lammi-Keefe; P W Wilson; T Massov; E J Schaefer
Journal:  Clin Chem       Date:  1996-04       Impact factor: 8.327

9.  Assay of total plasma apolipoprotein B concentration in human subjects.

Authors:  G Schonfeld; R S Lees; P K George; B Pfleger
Journal:  J Clin Invest       Date:  1974-05       Impact factor: 14.808

10.  Factors associated with low and elevated plasma high density lipoprotein cholesterol and apolipoprotein A-I levels in the Framingham Offspring Study.

Authors:  E J Schaefer; S Lamon-Fava; J M Ordovas; S D Cohn; M M Schaefer; W P Castelli; P W Wilson
Journal:  J Lipid Res       Date:  1994-05       Impact factor: 5.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.